Abstract. Parenteral long-acting lipophilic solutions have been used for decades and might in the future be used in the design of depots with tailored delivery characteristics. The present review highlights major factors influencing the in vivo performance of lipophilic solutions. Furthermore, an account is given of the characteristics of employed in vitro release methods with a focus on the "state" of sink condition, the stirring conditions, and the oil-water interfacial area. Finally, the capability of in vitro release data to predict the in vivo performance of drug substances administrated in the form of lipophilic solutions is discussed. It is suggested that as long as the major rate-limiting in vivo release mechanism is governed by the drug partitioning between the oil vehicle and the tissue fluid, the use of in vitro release testing in quality control appears to be realistic. With increasing lipophilicity of the drug substances and longer duration of action, the in vivo drug release process may become more complex. As discussed, practical analytical problems together with the inability of release methods to mimic two or more concomitant in vivo events may constitute severe impediments for establishment of in vitro in vivo correlations.
INTRODUCTION
Parenteral long-acting lipophilic solutions (mainly for intramuscular injection) have been in clinical use for more than 3 decades in the field of schizophrenia and hormone replacement therapy (1) (2) (3) . Prolonged duration of action is accomplished by employing a suitable vegetable oil-containing vehicle and a lipophilic prodrug derivative of the parent drug (Table I) (4) . Compared with other parenteral depot principles, key attributes of such relatively simple oil-based solutions include uncomplicated manufacture (including terminal sterilization) and feasible long-term stability. Also, this formulation principle opens up the possibility of designing depots with tailored delivery characteristics since manipulation of oil-water distribution coefficients might be obtained through prodrug formation or optimization of oil vehicle composition (5) (6) (7) . Therefore, this type of formulation appears to be attractive not only for intramuscular injection of novel drug candidates which require transport to the target area via the systemic circulation but also to provide sustained local drug action, for example, in the joint cavity upon intraarticular administration (8) .
In vitro drug release models for lipophilic solutions could be used for formulation design purposes or in quality control (including establishment of in-vitro-in-vivo correlations (IVIVC)). Ideally, in vitro model development should be based on knowledge of the in vivo drug release mechanism(s) (9) (10) (11) . It is well established that the drug release rate from lipophilic solutions is, at least partly, governed by the drug partitioning between the oil vehicle and the tissue fluid (2, 3, (12) (13) (14) . However, several other factors, such as the shape of the depot at the injection site and the fate of the oil vehicle per se, might affect the overall pharmacokinetic fate of the therapeutic agent. The main objectives of the present review are (a) to highlight factors influencing the in vivo performance of lipophilic solutions (b) to comment on various in vitro release methods used in the characterization of lipophilic drug solutions, and (c) to discuss the capability of in vitro release data to predict the in vivo performance of drug substances administrated in the form of lipophilic solutions.
FACTORS INFLUENCING THE IN VIVO PERFORMANCE OF LIPOPHILIC SOLUTIONS
After depot instillation, the fate of the drug is potentially influenced by a number of processes (Fig. 1) . The relative importance of these may to some extent vary with the route of administration. The main focus of this contribution is on intramuscular (i.m.) depot injection, which is the preferred route of administration in human therapy. Several of the issues treated may be of equal importance for the understanding of the in vivo behavior of lipophilic solutions injected subcutaneously (s.c.). In the veterinary field, the subcutaneous injection is common practice (15) .
Disregarding local metabolic activity, the drug substance (or a prodrug derivative of the active pharmaceutical ingredient) can be removed from the site of administration by two different processes. The active agent may be released from the oil vehicle into the tissue fluid followed by transport to the microvessels, where the average length of diffusion to a capillary is influenced by the extent of spreading of the depot at the injection site. Alternatively, small oil drops containing the drug may be cleared from the local injection site by transport into the lymphatics. Where prodrugs are used, the site of prodrug conversion as well as uptake into fatty tissues ("second depot") may also have an impact on the shape of plasma profile of the parent drug as discussed in the sections below (Table II, Fig. 1 ).
Drug Partition from Lipophilic Solution to Tissue Fluid
Release of lipophilic drugs from oil vehicles is suggested to constitute the rate-limiting step governing the rate of drug appearance in the systemic circulation after intramuscular administration (2, 16, 17) . This transport process has been suggested to involve partitioning of the drug between the oil vehicle and the tissue fluid (2, 3, (12) (13) (14) . In support of this suggestion, linear relationships between log absorption rate and log oil-water distribution coefficient have been reported (18) (19) (20) (21) . Thus, the rate of drug release from the vehicle can be manipulated by choice of transport group for prodrug design and/or vehicle composition.
As to the exploitation of the prodrug approach, significantly different drug pharmacokinetics were observed following i.m. injection of sesame oil solutions containing buprenorphine base and the corresponding decanoate ester in rats (22) (Fig. 2) . The effect of variation of the chemical structure of the transport group on in vivo depot properties has been reported for a few drugs only. Duration of action of zuclopenthixol acetate and decanoate dissolved in fractionated coconut oil (Viscoleo®) were 2-3 days and 2-4 weeks, respectively (23) . Likewise, in rats, i.m. injection of ester derivatives of buprenorphine resulted in longer absorption half-lives with increasing ester lipophilicity (22) (Fig. 2) . Also in case of fluphenazine and testosterone, animal studies have revealed enhanced plasma residence times of the decanoate esters compared to those of the corresponding enanthate esters (16, 24) .
Employment of different oil vehicles may affect absorption rates to a minor extent following i.m. and s.c. injection.
Several in vivo studies have been conducted (18-20,25-28; see for instance Fig. 3 ), though the reported data do not allow for a ranking of the various vehicles with respect to their prolonged release capabilities.
Spreading of the Lipophilic Solution at the Injection Site
At the site of injection, solute transfer from the oil phase into the tissue fluid requires drug transport (diffusion in oil vehicle) to the oil-tissue fluid interface followed by partitioning into the aqueous phase. Thus, vehicle viscosity and the interfacial area between the oil and aqueous phase are determinants of the total amount of drug released per time unit. Upon i.m. injection, significant spreading (and consequently increase of interfacial area) along the muscle fibrils takes place. Moreover, s.c. injection leads to spreading and dispersion of lipophilic solutions (19, 20, 29, 30) . Minimal drug release per unit volume of oil vehicle might be observed in body compartments such as the joint where the original oil drop shape is expected to be at least partly restored. Additional factors that potentially might affect the spreading of the depot formulation include the physiology of the injection site (14, (31) (32) (33) , injection volume (19, 20, 26) , the 
Lymphatic and Second Depot Uptake
After i.m. injection (rats) of sesame oil solutions of fluphenazine (13,34) and haloperidol (35, 36) , in the form of their decanoic acid esters, drugs were detected in the lymph system with the highest concentrations found in the lymph nodes close to the injection site. It was suggested that small oil drops containing the drugs were most likely absorbed by the local lymphatic system followed by drug release from the depot (Fig. 1) . In contrast, the presence of drug in peripheral lymph nodes was most likely a result of drug uptake from the blood (13, 35, 36) . Enhanced drug residence time in the blood might also be brought about by drug uptake from the systemic circulation into so-called second depots including fatty tissue (12, 21) , entero-hepatic circulation (18) and protein binding (37, 38) .
Additional In Vivo Events Potentially Affecting the Rate of Drug Appearance in the Systemic Circulation
The clearance of various oil vehicles from the i.m. and s.c. injection sites have been investigated in various animal species, revealing half-lives of disappearance in the range of 2-30 days (26, 29, 30, (39) (40) (41) . In most cases, fractionated coconut oil was cleared faster from the injection site than other oil vehicles investigated (29, 30, 41) . In Table III , representative oil dis- Affects the absorption rate by changing the surface-to-volume ratio of the oil vehicle at the injection site (further studies are needed) Viscosity of the oil vehicle Currently, no correlation between oil viscosity and absorption (and release) rate has been found Diffusion of drug in oil vehicle
To be clarified Drug transport in tissue fluid by diffusion/convection Dictate the "degree" of sink conditions in the vicinity of the injection site Disappearance of oil vehicle from the injection site Has to be considered primarily for highly lipophilic drugs Hydrolysis of ester prodrug at the oil/tissue fluid interface Possible release mechanism mediated by lipases Fig. 2 . Plasma concentration-time profiles of buprenorphine in plasma after intramuscular injection of parent buprenorphine and the propionate, enanthate, and decanoate esters in sesame oil in rats.
Values are expressed as mean ± SEM (n=3). Reprinted with permission from (22) Time (days) Fig. 3 . Serum concentrations (mean ± SEM) of testosterone after single-dose intramuscular injection of 1,000 mg testosterone undecanoate in tea seed oil in seven hypogonadal men (filled square) or castor oil in 14 hypogonadal men (empty circle). Broken lines indicate normal range of testosterone. Reprinted with permission from (25) appearance half-lives are given. There were obtained by monitoring the amount of 125 I-labeled oil remaining at the i.m. injection site (in pigs) as a function of time by non-invasive gamma-scintigraphy (29) . As previously mentioned, removal of the drug substance from the tissue site may be a result of two parallel processes. The drug may be released from the oil vehicle into the tissue fluid followed by transport to the microvessels, and small oil drops containing the drug may be cleared from the local injection site by transport into the lymphatics. Hence, the contribution of the latter (slow) process to the overall rate of disappearance from the injection site is expected to increase with increasing lipophilicity of the drug. Likewise, local metabolic degradation of the oil vehicle might also affect the in vivo performance of the depot products.
In the field of oil depot injectables, exploitation of the prodrug approach may be used to tailor the rate of drug release from the vehicle. Also, prodrug derivatization constitutes a means to provide the necessary oil solubility. 
Continuous flow methods
The lipophilic formulation floats on the release medium. The medium is circulated through the cell. Reprinted with permission from (73) f Reprinted with permission from (68) Hydrolysis of the ester prodrug bond is not usually considered to be the rate-limiting step in the overall absorption process, except for the (hypothetical) situation involving parent drug regeneration at the oil-tissue fluid interface as a result of enzyme-mediated cleavage of the prodrug ester bond. Especially for highly lipophilic prodrug derivatives such enzyme-facilitated hydrolysis might lead to unexpectedly fast release of the less lipophilic parent drug. Lipases which are active at oil-water interfaces have been shown to hydrolyze ester derivatives (for example triglyceride-like conjugates (42) (43) (44) (45) and fatty acid esters (46)) at oil/water interfaces in vitro.
Minor changes in the formulation or the manufacturing process may result in the introduction of new chemical substances in the depot formulation. Such "impurities" may be a result of shifts in supplier of a pharmaceutical excipient, for example, or in the degradation profile of the product due to alteration in the sterilization procedure. Unless embraced by the specifications, even small amounts of impurities may in principle affect several of the above-mentioned factors, as well as the host response, and may therefore cause non-predictable variability in drug pharmacokinetics. Since the effect of changes in host response cannot be simulated by using an in vitro release model, the adequacy of a change in formulation/ manufacture should preferably be documented by bioequivalence studies performed in a suitable animal model.
IN VITRO RELEASE TESTING
No regulatory approved standard methods exist for testing drug release from sustained release parenteral products, despite the long-recognized need for such in vitro release methods (9, 10) . For oil-based injectables, the release models used (Table IV) Comparison of release data obtained by using the various methods is far from straightforward, since different experimental setup influence three key parameters (oil-water interfacial area, hydrodynamics (stirring conditions) and "state of sink condition") differently, as discussed in the paragraphs below.
Oil-Water Interfacial Area
The drug release rate is proportional to the total oilwater interfacial area. Thus, this parameter should ideally be kept constant during the release process. This can be effectuated by using models with the oil phase floating on the release medium. In this type of model, the area may easily be altered by inserting tubes/cubes of different sizes/geometries (47) (48) (49) . As regards the dialysis techniques, the interfacial area for mass transfer is equal to the total membrane area as long as an amount of oil sufficient to cover the entire inner surface is added to the donor compartment (6, 7, (50) (51) (52) . Conversely, if the lipophilic solution is added to a donor cell containing an aqueous buffer, proper agitation may create a very large oil-water interface (53-56) (Fig. 4) . In such a case, equilibrium of partitioning between the oil and aqueous phase is maintained at all times in the dialysis cell. For this reason, determinations of the drug partition coefficient may eventually replace release experiments. Decisions have to be made on case-by-case basis, preferably based on a dialog between the company and the regulators. In the present context, the applicability of continuous flow methods, in general, seems to be questionable due to difficulties in controlling the interface between oil vehicle and the aqueous phase. One exception might be the flow-through cell initially developed for in vitro release testing of suppositories (57) (58) (59) .
Stirring Conditions
Agitation of the acceptor compartment is a prerequisite for maintaining homogenous drug concentrations in the aqueous release medium. However, stirring of the oil phase might be left optional, depending on the in vivo conditions to be mimicked. In release studies characterized by an unstirred oil phase floating either on the release medium (60) or at the ceilings of a flow-through cell (59), linear relationships between percent drug released (up to 30%) and square root of time were observed. These observations led to the (speculative) suggestion that solute diffusion in the unstirred oil phase to the oil-water interface is the rate-determining step in the overall release process. In contrast, drug transfer rates from the oil to the aqueous phase obeyed first-order kinetics using models characterized by stirring of the oil phase (6, 7, (49) (50) (51) (53) (54) (55) 61, 62) .
Sink Conditions
The impact of maintaining sink conditions during in vitro release testing of sustained release products has been subject to debate (see for example the reviews (11, (63) (64) (65) ). According to the USP, sink condition is defined as being one third of the saturation value (66) . Alternative definitions include that the bulk drug concentration during the entire release process should not exceed 10% of the drug saturation concentration. Exploitation of sink conditions during in vitro release experiments may ease the mathematical analyses (65, 67) . On the other hand, the relevance of such model conditions may be questionable since perfect sink conditions are less likely to prevail locally at the site of administration of the depot formulation (53, 55, (63) (64) (65) 67) . In this context, it might be mentioned that excellent quantitative descriptions of in vitro drug release rates from lipophilic solutions under non-sink conditions have been accomplished using the rotating dialysis cell model (6, 50, 51, (53) (54) (55) . If release testing under approximated sink condition is desirable, flow-through systems might appear attractive (59) . Also, the reverse dialysis bag method previously used for measuring drug release rates from emulsions (68,69) might be advantageous.
CAPABILITY OF IN VITRO RELEASE DATA TO PREDICT IN VIVO DRUG PERFORMANCE
Design of a suitable in vitro release model is a key activity in the development of a novel parenteral depot formulation. In the Chemistry, Manufacturing, and Control (CMC) regulatory file, the pharmaceutical company needs to convince regulatory agencies of the adequacy of the discriminatory release model constructed for use in batch release. Optimally, batch variations which would lead to unacceptable changes in, for example, the pharmacokinetic profile of the drug should be reflected in the in vitro release behavior. At best, the in vitro model may mimic the in vivo conditions to such an extent that a level A IVIVC can be established. In this case, performance of in vitro release tests might be accepted instead of an in vivo bioequivalence study (biowaiver) for the evaluation of minor changes in the composition or manufacturing process of an already marketed product. In the field of lipophilic solutions, apparently only one attempt to establish an IVIVC has been reported in the literature. A relation between in vitro and in vivo drug release was demonstrated for an oil solution containing bupivacaine (a moderate lipophilic drug), which showed an analgesic effect lasting for about 1 day (70) . The lack of true IVIVCs can most likely be ascribed to barriers related to intrinsic drug properties or the inability to design in vitro methods sufficiently capable of mimicking the in vivo conditions at the injection site.
Attributes of highly lipophilic drugs (or prodrug derivatives) include high vegetable oil solubility and slow partitioning from oil vehicles into an aqueous phase. However, such compounds may exhibit extremely low aqueous solubility. The latter physicochemical property may make in vitro release testing of highly lipophilic drug substances problematic. This analytical challenge relates to detection of the compounds as well as performance of release experiments endowed with acceptable run times. These problems might to some extent be reduced by introducing a means to enhance drug solubility in the release medium (such as addition of cyclodextrin (7)). Also, faster drug release from the lipophilic formulation might result from enhancing the oil-water interfacial area (this approach might also be suitable for accelerated in vitro release testing) (55) .
In vivo phenomena which are difficult to simulate using an in vitro release model include spreading and dispersion of the oil vehicle at the injection site. Variable spacial expansion of the depot at the injection site (and thus creation of variable interfacial areas of drug transfer) is dictated mainly by the injection technique and the choice of specific administration site. Hence, variable vehicle spreading, per se, is not considered a drug product quality issue, although this parameter may indeed affect drug release rates. Also, the situation, where two or more events in parallel contribute to the overall rate of disappearance of the drug from the injection site, may be difficult to mimic in vitro. Transport of microdroplets containing the drug to the lymphatics and enzyme-mediated prodrug cleavage at the oil surface may represent examples of such contributing processes. Apparently, little is known about the clearance of different oil vehicles from the injection site in humans, and to which extent host responses affect the disappearance rates. Animal studies (in pigs) have revealed only minor differences in disappearance rates of various vegetable oils with half-lives of about 14 to 23 days (29) . Often, it has been emphasized that in vitro release model development should be based on knowledge of the in vivo drug release mechanism (9-11). So far, elucidation of effects of hydrodynamics, convective diffusion mass transfer and "state of sink condition" on drug fate at the injection site is still lacking.
In case of relatively short-acting oil depots comprising moderately lipophilic drug substances the generation of in vitro release data for prediction of in vivo drug performance appears reasonably realistic given that drug release from the lipophilic vehicle constitutes the rate-limiting step in vivo. For long-acting depot formulations, the disappearance of the oil containing the drug from the injection site (and potentially other drug release processes) contributes to the overall rate of drug release from the local administration site. The latter in vivo conditions are difficult to simulate by use of an in vitro drug release model and may become prohibitive for the establishment of an IVIVC.
CONCLUSION
Although parenteral long-acting lipophilic solutions have been used for intramuscular administration for several decades, the in vivo drug release mechanism(s) are far from fully elucidated. To this end, literature data may suggest the involvement of two major contributing in vivo processes (a) drug release from the lipophilic solution governed by the partitioning of the drug between the oil vehicle and the tissue fluid and (b) disappearance of the oil vehicle containing the drug from the injection site. Alterations in these processes caused by formulation changes might therefore influence the overall in vivo performance of the drug product. In the case of relatively short-acting oil depots comprising moderately lipophilic drug substances, the generation of in vitro release data for prediction of in vivo drug performance appears to be reasonably realistic given that drug release from the lipophilic vehicle constitutes the ratelimiting step in vivo. With increasing duration of therapeutic activity, two or more in vivo events (including non-predictable host responses) may contribute to the overall drug release characteristics. Thus, it is suggested that the probability for successful development of a suitable in vitro release model (for batch control and IVIVC), so to speak, is inversely proportional to the intended duration of action of the lipophilic solution.
